Sponsors (4)
The bill pairs modest, targeted prize funding and federal coordination with nonbinding, stakeholder-focused policy to encourage better Lyme disease awareness, diagnostics, and care — but because it lacks binding mandates or substantial funding, its benefits are uncertain and likely limited in scale.
People with or at risk for Lyme disease gain a realistic chance of faster, more accurate diagnosis and improved prevention or treatment through combined stakeholder engagement, next-generation diagnostics emphasis, and a targeted HHS prize competition.
Researchers, entrepreneurs, and health systems receive new economic incentives and federal coordination (prize funding and HHS-led competitions) that encourage rapid innovation and speed commercialization of Lyme-related diagnostics, treatments, and prevention tools.
Increased public awareness and health education initiatives could lead to earlier detection and treatment of Lyme disease, reducing complications for affected patients.
The bill is largely a nonbinding policy statement with no mandates, timelines, or guaranteed funding, so promised improvements may not materialize and public trust could erode if expectations aren't met.
The $5 million appropriation for prize competitions is taxpayer-funded and may divert limited federal resources, yet is likely too small to reliably produce breakthrough diagnostics or treatments.
Without additional regulatory or sustained federal support, small businesses and nonprofits that invest in diagnostics, education, or commercialization in response to the policy may face financial risk if broader funding or market support doesn't follow.
Based on analysis of 3 sections of legislative text.
Introduced February 11, 2026 by Christopher Henry Smith · Last progress February 11, 2026
Creates a federal policy encouraging collaboration among academia, nonprofits, industry, small businesses, entrepreneurs, and government to support patient-centered innovation, public education, and faster, next-generation diagnostics for Lyme disease. Authorizes up to $5,000,000 to be appropriated to the Department of Health and Human Services to run prize competitions aimed at speeding innovation in prevention, diagnosis, and treatment. The bill is primarily a policy statement and a small funding authorization for prize challenges; it does not create new mandates, assign specific agencies or deadlines beyond HHS authority to run competitions, or directly change regulations or benefit programs.